Jonathan Jackson - 20 Jun 2023 Form 4 Insider Report for Histogen Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 20 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jun 2023, 16:08:39 UTC
Prior SEC filing: 03 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Susan A. Knudson as attorney-in-fact for Jonathan Jackson

Key filing fact

Jonathan Jackson filed Form 4 for Histogen Inc. on 21 Jun 2023.

Key facts

This page summarizes Jonathan Jackson's Form 4 filing for Histogen Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jun 2023, 16:08.

Change

Previous filing in this sequence was filed on 03 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HSTO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +6,835
Change %
Price: $0.000000
Shares after: 6,835
Date: 20 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,835
Exercise price: $0.8280
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was issued to the Reporting Person, a non-employee director of the Issuer, for his service as a director of the Issuer.

Footnote F2

The shares subject to this option become fully vested and exercisable on 6/20/2024, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.